simplebooklet thumbnail

of 0
Investor Presentation Transforming Medicine  Senescent cell clearance as a novel therapeutic treatment for aging-associate...
SIWA THERAPEUTICS AND SLOWING OF AGING We began SIWA to develop therapies for slowing or reversing the aging process by pr...
SIWA Therapeutics is  A Pre-Clinical Stage Company With      A first-in-class humanized monoclonal antibody, SIWA 318, tha...
Advancing Anti-Senescent Antibody Toward Clinic HIGHLIGHT Lead antibody  SIWA 318   4  DETAILS Targets SIWA-identified cel...
Senescence Causally Implicated In Multiple Diseases Causally implicated in or contributory Exacerbates and or causally imp...
Senescent Cells Promote Diseases Based On Tissue In Which They Occur Senescent Cells                   Lose function and a...
Images Of Senescent Cells And Non-Senescent Cells  blue shows SAB galactosidase staining   As cells become senescent, they...
SIWA 318 Overview  A Therapeutic Approach R D Progress to Date  Preclinical in vivo studies have shown using a mouse form ...
SIWA 318  Reduces Muscle Wasting In Naturally Aged Mice Statistically Significant Increase in Muscle Mass Statistically si...
SIWA 318  Reduces Senescent Cells In Naturally Aged Mice Statistically significant reduction in standard senescent cell bi...
SIWA 318  Senescent Cell Clearing Inhibits Tumor Metastasis Statistically significant inhibition of lung foci Key Findings...
SIWA Pipeline Research Cancer Osteoarthritis  Musc. Dystr. Alzheimer   s  Diabetes  12  Preclinical  Phase I
Growing Global IP Position      Earliest priority on patent filings worldwide for clearing senescent cells       First pat...
Other Products For Generating A Revenue Stream To Help Support Drug Development Work Toxin conjugated single domain molecu...
Key Personnel Lewis Gruber Founder, Director, Chief Executive Officer and Chief Scientific Officer.  Co-Founder and former...
Anticipated Business Developments Secure Funding     Initiate IND enabling studies      Continued execution and expansion ...
Recent Liquidity Events Cancer and Rare Disease Issuer  Symbol   IPO Date  IPO Price Raise  Current Price   Market Cap   S...
Competitors   None Developing A Pan Anti-Senescent Cell Antibody 1.  Mount Tam Biotechnologies www.mounttambiotech.com    ...
EXIT STRATEGY  The most probable near term liquidity events include               Separatory applications such as removing...